Crestline Management’s Moderna MRNA Stock Holding History

Crestline Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3,000	Closed	-$193K	–	158
2020 Q2	$193K	Buy	+3,000	New	+$164K	0.04%	142

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Crestline Management's MRNA Position: Q1 2025 in Review

Crestline Management sold out of Moderna (MRNA) in Q1 2025, closing a stake of 19,139 shares — an estimated $796K sold.

Crestline Management first reported a position in MRNA in Q4 2024 and held it in 1 quarter. The position peaked at $796K in Q4 2024. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

Crestline Management reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
Crestline Management sold 19,139 Moderna shares in Q1 2025, an estimated $796K.
Crestline Management first reported a position in Moderna in Q4 2024 and held it in 1 quarter.
Crestline Management's Moderna position peaked at $796K in Q4 2024.
693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.